KORR DANIEL
No ORCID on file
· 42 papers in corpus
· active 2008-2009
Frequent coauthors
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2009
The present invention relates to the single use of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…
2008
The present invention relates to the single use of the progesterone-receptor antagonist 11ss-(-4-acetylpheny)-17 ss-hydroxy-17a-(1,1,2,2,2-pentafluoroethyl)- estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue there…